COMMUNIQUÉ DE PRESSE
News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)
Quantum BioPharma announces approval to proceed with dosing of second cohort in Lucid-21-302 trial. Company focused on innovative treatments for neurodegenerative disorders -
-
-
COMMUNIQUÉ DE PRESSE
Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million
Quantum BioPharma announces a non-brokered private placement offering of convertible debenture units. Proceeds for business development and working capital
